United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $300.31, for a total transaction of $3,303,410.00. Following the completion of the transaction, the executive vice president owned 36,781 shares in the company, valued at approximately $11,045,702.11. This trade represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Stock Down 0.3%

Shares of United Therapeutics stock traded down $0.83 on Thursday, hitting $297.33. The company's stock had a trading volume of 459,518 shares, compared to its average volume of 442,900. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $417.82. The firm has a fifty day moving average price of $300.61 and a 200-day moving average price of $318.55. The company has a market capitalization of $13.41 billion, a P/E ratio of 11.86, a price-to-earnings-growth ratio of 6.52 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping the consensus estimate of $6.29 by $0.34. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The business had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. During the same period in the previous year, the firm earned $6.17 EPS. The business's revenue for the quarter was up 17.2% compared to the same quarter last year. As a group, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in United Therapeutics by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company's stock valued at $1,374,001,000 after purchasing an additional 15,312 shares during the last quarter. FMR LLC raised its stake in United Therapeutics by 36.5% in the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after purchasing an additional 393,777 shares during the last quarter. Geode Capital Management LLC raised its stake in United Therapeutics by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock valued at $401,184,000 after purchasing an additional 44,277 shares during the last quarter. AQR Capital Management LLC raised its stake in United Therapeutics by 0.8% in the 4th quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock valued at $344,176,000 after purchasing an additional 7,710 shares during the last quarter. Finally, Alliancebernstein L.P. raised its stake in United Therapeutics by 28.5% in the 4th quarter. Alliancebernstein L.P. now owns 709,043 shares of the biotechnology company's stock valued at $250,179,000 after purchasing an additional 157,363 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Bank of America lowered their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday, June 11th. HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. Cantor Fitzgerald started coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 target price on the stock. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $383.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.